The transcription factor CREB (cAMP Response-Element Binding Protein) is overexpressed in the majority of acute myeloid leukemia (AML) patients, and this is associated with a worse prognosis. Previous work revealed that CREB overexpression augmented AML cell growth, while CREB knockdown disrupted key AML cell functions in vitro. In contrast, CREB knockdown had no effect on longterm hematopoietic stem cell activity in mouse transduction/transplantation assays. Together, these studies position CREB as a promising drug target for AML. To test this concept, a small molecule inhibitor of CREB, XX-650-23, was developed. This molecule blocks a critical interaction between CREB and its required co-activator CBP (CREB Binding Protein), leading to disruption of CREBdriven gene expression. Inhibition of CBP-CREB interaction induced apoptosis and cell-cycle arrest in AML cells, and prolonged survival in vivo in mice injected with human AML cells. XX-650-23 had little toxicity on normal human hematopoietic cells and tissues in mice. To understand the mechanism of XX-650-23, we performed RNA-seq, ChIP-seq and Cytometry Time of Flight with human AML cells. Our results demonstrate that small molecule inhibition of CBP-CREB interaction mostly affects apoptotic, cell-cycle and survival pathways, which may represent a novel approach for AML therapy.
INTRODUCTION
Acute myeloid leukemia (AML) is associated with a 5-year overall survival of less than 50% despite the use of intensive chemotherapy regimens and hematopoietic stem cell transplantation. [1] [2] [3] Treatment for AML is itself associated with significant morbidity and mortality, and most patients who survive experience at least one serious treatment-related longterm complication. 4 Therefore, it is critical to identify novel therapeutic targets and develop more effective, less toxic drugs for the treatment of patients with AML.
Previous work has described the transcription factor CREB (cAMP Response-Element Binding Protein) as a critical regulator of the growth and survival of AML cells. [5] [6] [7] [8] [9] Elevated CREB expression was observed in~60% of AML patients, and this was associated with a significantly worse prognosis and an increased risk of relapse compared to patients with basal CREB expression. 8 CREB overexpression in AML cells augments their growth rate and confers resistance to apoptosis in vitro. 6 Conversely, CREB knockdown inhibited AML cell proliferation and induced apoptosis, but had no toxicity to normal hematopoietic stem cells in mouse transplantation assays. 10 Together, these observations suggest that CREB is associated with a more aggressive form of AML, yet is not required for normal hematopoietic stem cell function. Therefore, we hypothesized that inhibition of CREB function may represent an effective, targeted approach to AML therapy.
CREB binds genomic DNA at thousands of loci possessing the consensus cAMP Response Element (CRE). 11 Initiation of CREB-driven transcription at these loci requires that CREB recruits and binds a co-activator, the histone acetyltransferase CREB-Binding Protein (CBP). 5 This interaction triggers local histone acetylation and subsequent recruitment of transcriptional machinery to the promoter. 12 Thus, our group sought to disrupt the critical interaction between CREB and CBP in an effort to disrupt CREB-driven transcription.
The precise molecular interactions that mediate CBP-CREB binding have been resolved by NMR spectroscopy, 13, 14 which facilitated the identification of a small molecule capable of disrupting the CBP-CREB interaction, naphthol AS-E phosphate (KG-501). 15 Although the low potency of KG-501 renders it a poor candidate for potential clinical use (K i~9 0 μM), this molecule provided a molecular backbone for further development. 16 Through a series of structure-activity relationship studies, we designed 'XX-650-23' [N-(4-cyanophenyl)-3-hydroxy-2-naphthamide], an inhibitor of the CBP-CREB interaction. [17] [18] [19] [20] The current studies were undertaken to determine the efficacy of targeting the CBP-CREB interaction in AML therapy, and evaluate the toxicity of this approach to normal cells.
Here, we provide evidence that XX-650-23 disrupts the CBP-CREB interaction in AML cells and elicits an array of ontarget transcriptional alterations, which leads to cell-cycle arrest and apoptosis of AML cells in vitro and significantly increases survival of cell line-and patient-derived xenograft mice with no toxicity to normal hematopoietic cells or animals. These data provide 'proof-of-principle' that CREB inhibition represents a potential approach for AML treatment.
MATERIALS AND METHODS
Protein purification and biacore KIX domain mutants were created by standard cloning and mutagenesis methods in the pGEX4T3 vector (GE Healthcare Life Sciences, Pittsburgh, PA, USA). GST-KIX and its mutants were purified with the B-PER GST Fusion Protein Spin Purification Kit (Thermo Scientific/Pierce, Grand Island, NY, USA). Surface plasmon resonance analysis was performed on a GE Biacore 3000 surface plasmon resonance instrument in collaboration with the Stanford Protein and Nucleic Acid (PAN) Facility.
AML cell lines and patient samples
KG-1, HL-60, MOLM-13, MV-4-11 and U937 cell lines were obtained from ATCC, and low-passage stocks were used and cultured for less than 3 months. Cells were regularly tested for Mycoplasma and growth characteristics, though no further authentication has been performed by the authors. Cells were plated at a density of 2-4 × 10 5 cells/ml, and treated with various doses of XX-650-23. Cell counts and viability were determined using the Vi-CELL XR Cell Viability Analyzer (Beckman Coulter, Brea, CA, USA). HL-60 and KG-1 cells overexpressing CREB were generated using lentiviral gene delivery with subsequent cells sorting for GFP. CREB knockdown was achieved by infecting cells with a lentivirus expressing the shRNA sequence 5′-GCAAATGACAGTTCAAGCCC-3′. For chemotherapy combination experiments, combination index values were calculated using median effects analysis on Calcusyn software as described. 21 Human patient bone marrow samples were cultured in DMEM plus 20% FBS and 1 × PSG, supplemented with recombinant GM-CSF (20 ng/ml), G-CSF (20 ng/ml), SCF (50 ng/ml), IL-3 (20 ng/ml) and IL-6 (10 ng/ml). Cells (1 × 10 5 cells/ml) were cultured with XX-650-23 for up to 72 h. All samples contained 485% AML blasts and were not sorted before performing experiments. Flow-cytometry analyses were performed on a DxP10 flow cytometer (Cytek, Fremont, CA, USA). All antibodies were purchased from BD Biosciences (San Jose, CA, USA). Bone marrow from AML patients was collected through voluntary patient participation at University of California, Los Angeles (Los Angeles, CA, USA) and Stanford University (Palo Alto, CA, USA) in compliance with the Institutional Review Board regulations of each institution. Informed consent was obtained from all human subjects, and all research was conducted in accordance with the statements set forth in the declaration of Helsinki and the Data Protection Directive.
Luciferase assays
KG-1 cell lines were created to express luciferase in a CREB-dependent or non-CREB-dependent manner using lentiviral gene delivery. Cells were sorted for mCherry expression. Luciferase activity was measured on a spectrophotometer using the Promega Luciferase Activity Kit (Promega, Madison, WI, USA) as per manufacturer's instructions. The split-Renilla luciferase complementation assay has been described previously. 20 In this assay, the KID and KIX domains were fused to the N-and C-terminal regions of Renilla luciferase, respectively. Once KIX binds phosphorylated KID, the Renilla luciferase regions were brought together, resulting in luciferase activity.
Cell-cycle analysis
KG-1 cells were synchronized at prometaphase using a modified thymidine plus nocodazole block. 22 Briefly, KG-1 cells were treated with 2 mM thymidine for 30 h, washed with PBS and released from G 1 /S block in fresh media for 4 h. The cells were incubated with 300 nM nocodazole (Sigma, St Louis, MO, USA) for 13 h. XX-650-23 or DMSO was added 3 h before release. The synchronized cells were washed with PBS and released from the mitotic block in fresh media containing XX-650-23 or DMSO. To analyze DNA content by flow cytometry, cells were harvested, fixed in 70% ice-cold ethanol for at least 1 h at − 20°C, and then stained with propidium iodide. Cells were analyzed on an FACS Calibur flow cytometer (BD Biosciences). Cell-cycle distribution was determined using FlowJo software (TreeStar, Ashland, OR, USA).
Chromatin immunoprecipitation and high-throughput sequencing (RNA-Seq and ChIP-Seq) For Chip-Seq experiments, KG-1 cells were treated with 5 μM XX-650-23 or DMSO for 6 h. Cells were crosslinked with 1% formaldehyde at room temperature for 10 min and then incubated with 0.125 mM glycine for 5 min. After crosslinking, chromatin was digested by Micrococcal nuclease and then sonicated using SimpleChIP Plus Enzymatic Chromatin IP Kit (Cell Signaling, Danvers, MA, USA) following the manufacturer's protocol. Chromatin immunoprecipitations were carried out with anti-CREB antibody (17-600, Millipore, Billerica, MA, USA), anti-Acetyl-Histone H3 (8173, Lys27) (D5E4) (Cell Signaling Technology) or a control IgG (Santa Cruz Biotechnology, Santa Cruz, CA, USA). The captured immunocomplexes containing bound transcriptional DNA fragments were eluted, with recovered DNA fragments used for PCR amplification. For RNA-Seq experiments, KG-1 cells were treated with XX-650-23 (5 μM) or 0.1% DMSO for 12 h. Sample libraries were run using the Illumina sequencing platform. Two hundred million reads were collected on two biological replicates of the experiment. Libraries were prepared using the Illumina Truseq RNA samples prep kit as per manufacturer's instructions. Fastq files were aligned using TopHat. 23 Aligned BAM files were used for CuffDiff calculation of differentially expressed genes. 24 CummeRbund R package was used to infer QC of the RNA-seq. RNA-seq and CREB ChIP-Seq data were deposited in the NCBI GEO database (GEO submission GSE74928). ChIP-seq analysis was performed as previously described. 25 BETA analysis was used by inferring differentially expressed genes between DMSO-and XX-650-23-treated cells based on an fdr of ⩽ 0.01 and a gene distance of 100 kb (Galaxy/cistrome). For analysis of RNA-seq data as target genes of known transcription factors, a curated list of all human target genes was extracted from the TRANSFAC Pro database. DNA sequences enriched on ChIP-Seq were defined as previously published. 26 
RT-PCR
Total RNA was isolated using the Aurum RNA Isolation Mini Kit, and the iScript cDNA Synthesis Kit was used to prepare samples for qPCR (Bio-Rad, Hercules, CA, USA). Data were analyzed using the Livak method. 27 Data were normalized to 7SL scRNA expression values.
Western blot analysis
Cell lysates were resolved on SDS-PAGE gels, and then transferred onto PVDF membranes (Millipore). Listing of primary antibodies is given in Supplementary Table 1 . Secondary antibodies were used at a 1:2500 dilution and purchased from Thermo Scientific/Pierce. Membranes were visualized with an enhanced chemiluminescence system. Representative blot of at least three different experiments is shown.
Hematopoietic cell colony assays
Normal human bone marrow cells were resuspended in methylcellulose (2 × 10 4 cells/ml, Miltenyi Biotec, Auburn, CA, USA) containing cytokines (GM-CSF, G-CSF, IL-3, IL-6, SCF, erythropoietin), and cultured for 2 weeks. Colonies were scored on the basis of morphology.
Caspase-3 activity
The ApoTarget Caspase-3 Protease Activity Kit (Invitrogen, Grand Island, NY, USA) was used as per manufacturer's instructions.
Multiparameter single cell mass cytometry (CyTOF)
Bone marrow from primary AML patients was cultured as above and treated for 48 h with 2 μM XX-650-23. These were stained for viability using cisplatin as previously described. 28 Cells were fixed with 1.6% PFA for 10 min and washed with cell staining media. Fc receptor block was performed using Human TruStain FcX (Biolegend, San Diego, CA, USA). Cells were stained for surface proteins at room temperature for 30 min, and then cells were washed twice with cell staining media and permeabilized with methanol pre-cooled to 4°C for 10 min. Cells were then washed twice and stained for intracellular proteins for 30 min at room temperature. Cells were washed and stained with 1 ml of 2000 × iridium DNA intercalator (diluted 1:5000 in PBS with 1.6% PFA; DVS Sciences, Sunnyvale, CA, USA) overnight at 4°C. Data were acquired using internal metal isotope bead standards as previously described. 29 Cell events were acquired on a CyTOF I (DVS Sciences/Fluidigm). All antibodies were also purchased from DVS Sciences/Fluidigm. Each patient sample was individually normalized to the internal bead standards before analysis. To remove dead cells and debris, cells were gated based on cell length and DNA content as described. 30 
AML xenograft models of AML
For AML xenograft mouse experiments, HL-60 cells (2 × 10 6 ) expressing firefly luciferase and GFP, or cryopreserved human AML patient cells (5 × 10 6 ), were injected through the tail vein into NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NSG) mice (5-8 weeks old). AML cell-injected mice were randomly divided into two groups. Mice were then treated with XX-650-23 or 10% DMSO, injected intravenously (i.v.) daily, until death or an end point was reached (moribundity) in accordance with the animal care institutional guidelines. The sample size of AML xenograft mice experiments was determined based on our previous studies as well as the published papers. 31, 32 Blinding was not used for xenograft mice experiments. All mouse experiments were subjected to institutional approval by Stanford University Institutional Animal Care and Use Committee. Leukemia progression in mice at the indicated time points was monitored using an in vivo IVIS 100 bioluminescence/optical imaging system (Xenogen Corporation, Alameda, CA, USA). Analysis was performed on Living Image In Vivo imaging software (Perkin-Elmer, Waltham, MA, USA).
Statistical analysis
Unless noted, all experiments were performed in triplicate, and unpaired two-tailed Student's t-test was used to assess experimental mean values for statistically significant differences using Prism software (v5.04) (Graphpad, La Jolla, CA, USA), with P-values of o 0.05 deemed statistically significant. Kaplan-Meier plots and statistical significance of differences in mice survival experiments were calculated using a Log-rank (Mantel-Cox) test with Prism. Synergy calculations were performed using CalcuSyn software. IC50s were calculated using Prism.
RESULTS

XX-650-23 is a competitive inhibitor of CREB binding to CBP
The region of CBP critical for binding Ser133-phosphorylated-CREB is termed the Kinase-Inducible Acceptor domain or 'KIX' domain, and spans CBP amino acids 586-666. The small molecule KG-501 (Naphthol AS-E phosphate) was reported to disrupt CREB-CBP binding by interacting with key amino acids in the KIX domain, particularly residues Arg-600 to Valine-608. 15 On the basis of this information and subsequent structure-activity relationship studies, our group developed an optimized molecule targeted to this domain designed to disrupt the CREB-CBP interaction, termed 'XX-650-23' (Figure 1a ). Earlier structure-activity relationship studies revealed XX-648-48 as an inactive yet similarly structured compound (N-methyl-(4-chlorophenyl)-3-hydroxy-naphthamide). 20 Binding of XX-650-23 to the KIX domain and two KIX domain mutants in which residues critical for CREB binding were altered or removed (Arg-600 mutated to Alanine or deletion of amino acids 586-602) was determined by Surface Plasmon Resonance (Biacore) analysis ( Figure 1b ). Mutation of Arginine-600 to Alanine reduced binding of XX-650-23 by~45%, while a KIX domain mutant lacking amino acids 586-602 reduced binding by~70%. A hypothetical binding model between XX-650-23 and CBP KIX domain is shown (Figure 1c ). This binding model suggests that the major interactions between XX-650-23 and the KIX domain are hydrophobic. The aniline ring of XX-650-23 is predicted to project into a hydrophobic pocket of KIX where Leucine-141 of CREB, an amino acid essential for stable CREB binding, normally docks.
XX-650-23 inhibited the interaction between CREB and CBP with an IC 50 of 3.20 ± 0.43 μM in a split-Renilla luciferase complementation assay (Figure 1d ). 20 To determine whether XX-650-23 could specifically decrease CREB-driven reporter gene expression in AML cells, KG-1 AML cell lines expressing luciferase under the control of a CREB-driven promoter (two CRE elements placed upstream of an attenuated CMV promoter) or a CMV-driven promoter without CREs were treated with XX-650-23. CREB-driven luciferase activity was reduced by XX-650-23 in a dose-dependent manner, whereas CMV-driven luciferase expression was unchanged following treatment (Figure 1e ). The inactive analog XX-648-48 had no significant effect on luciferase activity in either AML cell line. Finally, we demonstrated that treatment of HEK293 lysates or cells with XX-650-23 prevented binding of CREB to CBP (Figure 1f ). Thus, XX-650-23 inhibits CREB function through disruption of CBP-CREB interaction.
XX-650-23 suppresses AML growth To test the effects of XX-650-23 on AML cells, four AML cell lines were treated with doses ranging from 100 pM to 10 μM for 48 h. The IC 50 of XX-650-23 for these AML cell lines, defined as a 50% reduced viable cell count compared with DMSO-treated cells after 48 h of culture, ranged from 870 nM to 2.3 μM (Figure 2a ). These four cell lines expressed CREB protein (Figure 2b ). We next tested the effects of XX-650-23 on primary human AML samples, obtained at initial diagnosis or at the time of relapse. AML patient samples treated with 2 μM XX-650-23 for 72 h demonstrated a range of responsiveness (Figure 2c ). AML patient samples with relatively higher CREB expression exhibited a greater loss of viability than those with lower CREB expression ( Figure 2d ). Normal bone marrow cells expressed nearly undetectable levels of CREB protein (Figure 2d ), and the viability of the cells did not significantly change by treatment with XX-650-23 (Figure 2c) . These studies were extended to methylcellulose colony assays of normal human hematopoietic cells, which also demonstrated no significant decrease in colony formation when treated with up to 10 μM XX-650-23 (Figure 2e ). These data indicated that higher CREB expression might be associated with greater sensitivity to XX-650-23. Therefore, we modulated CREB expression levels to determine whether we could change sensitivity of cells to XX-650-23. CREB was overexpressed, or knocked down by shRNA, in KG-1 cells (Figure 2f ). CREB knockdown in KG-1 cells decreased their sensitivity to XX-650-23, while CREB overexpression increased their sensitivity (IC50: CREB KD, 3.43 μM; GFP, 1.53 μM; CREB OE, 0.99 μM) (Figure 2g ). Experiments were also performed to examine the efficacy of combining XX-650-23 with cytarabine or daunorubicin, standard drugs used in AML therapy. The combination of XX-650-23 with cytarabine or daunorubicin in KG-1 cells showed a synergistic effect against KG-1 cell viability ( Supplementary Figure 1) .
XX-650-23 specifically disrupts CREB-driven transcription in AML cells
To determine the functional specificity and downstream effects of XX-650-23 in AML, the CREB transcriptome was first defined in KG-1 cells using CREB chromatin immunoprecipitation followed by high-throughput sequencing (CREB ChIP-Seq). In parallel, wholetranscriptome sequencing (RNA-Seq) of KG-1 cells treated with XX-650-23 was performed to define alterations in the transcription of identified CREB-bound genes. Finally, whole-genomic H3K27 histone acetylation analysis was performed to assess the disruption of CBP-CREB interaction. Together, these three experiments permitted: (1) assembly of a comprehensive catalog of CREB-bound sites within the AML genome; (2) identification of the set of genes that exhibited altered expression following XX-650-23 treatment and (3) measurement of alterations in CBP-mediated histone acetylation at genomic CREB-binding sites. In this way, the 'on-target' effects of XX-650-23 could be assessed.
CREB peaks (P-value ⩽ 10 − 5 , fdr ⩽ 1%) identified on ChIP-Seq analysis were enriched for the canonical 'CRE element' DNA binding sequence (Figure 3a) . CREB binding was detected at 4680 sites in the KG-1 AML cell genome. Nearly half of the CREB-bound genes (1863 of 4213 total CREB-bound genes) in KG-1 cells coincided with the previously reported putative CREB target genes. 11 Gene ontology enrichment analysis of the function annotations for regions associated with CREB-bound peaks (Supplementary Table 2 ) showed that CREB-bound peaks were enriched in clusters of genes regulating cell cycle and apoptosis as well as translation and mRNA processing. Over 90% of occupied CREB-binding sites were within 500 bp of a transcription start site ( Supplementary Figures 2A and B ). Of these CREB-bound 4213 genes, 2787 CREB-bound genes exhibited reduced expression following XX-650-23 treatment and 602 genes exhibited greater than 50% reduced expression. Majority of H3K27 peaks in CREB-bound genes (4052 out of 5282 total peaks) exhibited decreased H3K27 histone acetylation following treatment with XX-650-23 (66.5 ± 17% of control, n = 4052 peaks; Figure 3b and Supplementary Table 3 ). Histogram analysis of H3K27 acetylation of all CREB-bound genomic loci also showed a relative reduction in overall H3K27 acetylation, represented as a median shift to the left (Supplementary Figure 2C) . Moreover, reductions in H3K27 acetylation were almost exclusively within 1-3 kb of these CREB-bound promoter sites. On the contrary, the genes that did not show any significant binding site for CREB showed no global detectable changes in acetylation (Figure 3c ). CREB genomic binding did not change following XX-650-23 treatment (Figure 3d and Supplementary Figure 2D ). Western blot analysis confirmed that XX-650-23 caused a specific decrease in H3K27 acetylation and is not a general inhibitor of acetyltransferase activity (Figure 3e) .
To validate the RNA-Seq data set, qPCR of XX-650-23 target genes with CREB-bound promoters that exhibited significant (450%) transcriptional downregulation and reduced H3K27 acetylation was performed in two AML cell lines (KG-1 and HL-60) following treatment with XX-650-23 (Figure 3f and Supplementary Figure 2E ). XX-650-23 consistently reduced these target genes expression in both these cell lines in a statistically significant manner, although we expect that these genes are regulated by other transcription factors in addition to CREB. To assess for potential 'off-target' effects of XX-650-23, the RNA-Seq gene expression profiles of other transcription factors that bind CBP, including Rel, RelA, RelB, Foxo3, Foxo1 and Myb, were analyzed. XX-650-23 evoked no significant change in the expression of these CBP-binding transcription factor target genes (Figure 3g ). These results were confirmed for a set of Mybdriven genes, SP3, FPR1, PRODH and SLC34A2 in both KG-1 and HL-60 cells (Supplementary Figure 2F) . [33] [34] [35] [36] Thus, these results provide evidence that XX-650-23 disrupts the interaction of compared with those treated with vehicle alone (n = 10) beginning 1 day after AML cell injection (P = 0.0027, log-rank tests). (c) Kaplan-Meier curve analysis also demonstrated a survival advantage for mice given XX-650-23 (n = 10) compared with those treated with vehicle alone (n = 8) beginning 7 days after AML cell injection (P = 0.0211, log-rank tests). (d) RT-PCR showed that XX-650-23 elicits the same transcriptional alterations in vivo as observed in vitro. To directly evaluate the effects of XX-650-23 on CREB transcriptional activity in vivo, six NSG mice were injected with 2 × 10 6 HL-60 expressing GFP. After a 10-day engraftment period, the mice received three once-daily treatments of either 2.3 mg/ kg XX-650-23 or DMSO. The mice were then killed, and GFP + bone marrow cells were sorted and analyzed for transcriptional changes in validated CREB target genes. XX-650-23 treatment significantly reduced expression of all genes. Data are graphed as mean ± s.e.m. (n = 3), *P o0.05; **Po 0.01, t-test.
CREB to the KIX domain of CBP but not other KIX binding proteins in AML cells.
XX-650-23 prolongs survival in mouse models of AML without toxicity To examine the efficacy of XX-650-23 in an in vivo model of AML, NSG mice were tail-vein injected with HL-60 AML cells expressing Firefly luciferase and GFP. Mice received XX-650-23 (2.3 mg/kg, intravenously) once-daily starting the day after cell injection (immediate treatment groups), or starting 7 days after AML cell injection (delayed treatment groups). Bioluminescence imaging performed during treatment revealed less disease burden in XX-650-23-treated mice compared with control (average radiance measurements, given in p/s/cm 2 /sr: 5.7 × 10 5 for the control group versus 2.8 × 10 5 for the XX-650-23-treated group at day 17) (Figure 4a ). XX-650-23 significantly prolonged the median survival in Kaplan-Meier analysis in both the immediate (median survival, 22 days versus 31 days, P = 0.0027, long-rank test; mean survival 22.3 days versus 31.2 days) and delayed treatment groups (median survival, 20 days versus 24 days, P = 0.0211, longrank test; mean survival 20.9 versus 26.4 days) (Figures 4b and c) . We also assessed the efficacy of XX-650-23 in a mouse xenograft model using primary AML cell sample (patient sample #186). Mice treated with XX-650-23 demonstrated a significant survival advantage compared with DMSO-treated mice (Supplementary Figure 3A ). Next, we evaluated the effects of XX-650-23 on CREB transcriptional activity in AML cells in vivo. This experiment recapitulated in vitro findings (Figure 4d ).
Pharmacokinetic studies showed that the half-life of XX-650-23 in plasma is approximately 4.3 h (Supplementary Figure 3B) . XX-650-23-treated mice demonstrated normal complete blood counts, liver function tests and kidney function tests, compared with age-matched NSG mice given no treatment (Supplementary Figure 3C ). Histology demonstrated no microscopic evidence of vital organ damage (Supplementary Figure 3D) .
XX-650-23 induces apoptosis in AML cells
We next examined whether XX-650-23 induced cell death as well as growth inhibition in AML cells. In HL-60 cells treated with XX-650-23, apoptosis was induced in a dose-and time-dependent manner. Over 95% of cells entered early apoptotic or late apoptotic stage after 72 h of XX-650-23 treatment (Figure 5a ). To confirm that XX-650-23-induced apoptosis is not restricted to HL-60 cells, we determined the apoptotic effect of XX-650-23 in Patient 97 demonstrates activation of p-CREB in a cell-specific manner (white boxes) as well as no effect on Bcl-2 expression in CD34 + CD38 − population. In contrast, p-CREB and Bcl-2 expression levels were downregulated in CD34 + CD38 − population (green boxes) in patient 111, even though p-CREB level was increased (blue box) and Bcl-2 expression level was not changed (blue dashed box) in mature populations.
additional AML cell lines (KG-1, MV-4-11 and U937 cells). Apoptosis was observed in all these cell lines with XX-650-23 treatment ( Supplementary Figure 4) . XX-650-23 elicited apoptosis through the intrinsic apoptosis pathway, with activation of Caspase-3 ( Figure 5b ) and detectable Caspase-9 cleavage (data not shown). The balance between pro-and anti-apoptotic protein expression contributes to cell fate decisions. 37 CREB regulates the expression of several anti-apoptotic proteins, including BCL2, BCL2L1 and MCL1. 38, 39 The transcription of BCL2 decreased following 72 h of 2 μM XX-650-23 treatment (Figure 5c ), and this was verified by western blot analysis (Figure 5d ). In parallel, the expression of Mcl-1 initially increased, then decreased at 72 h, while Bcl-XL expression remained constant. Bcl-2 inhibitor ABT-737 treatment induced apoptosis, similar to XX-650-23 ( Supplementary Figures  5A and B) . 40 KG-1 cells also underwent apoptosis following treatment with XX-650-23, and similarly exhibited decreased Bcl-2 expression alongside a pronounced decrease in Mcl-1 (Figure 5d ). Bcl-2 levels were influenced by CREB expression in these AML cell lines (Supplementary Figure 5C ). Together, these data suggest that downregulation of Bcl-2 is involved in XX-650-23-induced apoptosis in AML cell lines.
We examined the relationship between Bcl-2, total CREB and p-CREB in primary AML patient samples, especially in the CD34 + CD38 − subpopulation containing the putative 'leukemia initiating' cells (see CyTOF gating strategy, Supplementary Figure 5D ). 41, 42 XX-650-23 treatment significantly reduced Bcl-2 expression levels in all cell subpopulations in XX-650-23 hyper-responsive primary AML cells with higher CREB expression (#96 and #186) (Figure 5e , within red outlined box). This occurred alongside downregulation of total CREB as well as reduced phosphorylation at Serine 133, an activation mark of CREB (Figure 5e , within yellow outlined box). In contrast, in patient sample 97, which expressed less CREB at baseline and showed less sensitivity to XX-650-23 (Figures 2c and  d) , CREB phosphorylation was increased in the CD34 + CD38 − population without significant Bcl-2 downregulation (Figure 5e , within white outlined boxes). However, p-CREB and Bcl-2 expression levels were downregulated in CD34 + CD38 − population (within green outlined boxes) in patient 111, even though phosphorylation of CREB was increased (Figure 5e , within blue outlined box) without significant Bcl-2 downregulation (Figure 5e , within blue dashed box) in the more mature AML cell populations. These data suggest that Bcl-2 downregulation in CD34 + CD38 − population may determine the sensitivity to the drug. The relative activation of AKT and ERK was associated with increased or decreased phosphorylation of CREB (Supplementary Figure 6A) . HL-60 cells also showed an increase in levels of phosphorylated but not total CREB following 24 h of XX-650-23 treatment (Supplementary Figure 6B) , and this effect can be blocked by validated small molecule inhibitors of the ERK and RSK kinases (Supplementary Figure 6B ), in keeping with previous work describing ERK/RSK-mediated phosphorylation of CREB downstream of the GM-CSF receptor in AML cells. [43] [44] [45] Blockade of these kinases increased the efficacy of XX-650-23 (Supplementary Figure 6C ). XX-650-23 induces AML cell-cycle arrest at the G 1 /S transition CREB regulates the cell cycle by virtue of transcriptionally regulating the expression of key cell-cycle genes. Following release from prometaphase, cell-cycle progression was followed by DNA contents for 24 h in the presence or absence of XX-650-23 in KG-1 cells. XX-650-23 treatment caused aberrant cell-cycle progression at the G 1 /S transition and through S phase (% cells in G 1 phase for DMSO-treated cells: 61.18 ± 0.97% and 4.92 ± 0.33% at 4 and 8 h, respectively, versus XX-650-23-treated cells: 66.20 ± 1.83% and 55.41 ± 0.59% (mean ± s.e.m., n = 3) at 4 and 8 h following release, respectively) (Figure 6a and Supplementary Figure 7A ). CyTOF cell-cycle analysis of AML patient bone marrow samples revealed the same perturbation in the G 1 /S transition following XX-650-23 treatment (Figure 6b ). The percent of cells in both the S and G 2 /M phases was reduced, and that of G 1 was increased.
A number of previously described mediators of the G 1 /S transition and S-phase progression were downregulated following XX-650-23 treatment, including a set of CREB-bound cyclins, CCNA2 and CCND1, and FOSL1 (Figures 3f and 6c ). [46] [47] [48] We analyzed RNA expression and H3K27 acetylation of CREBbound genes to identify potential target genes of XX-650-23 in cell-cycle perturbation. CREB-bound cell-cycle regulators including FOSL1, CDK2, CCNB1, CDC25C and RAD54L show decreased RNA expression and H3K27 acetylation following XX-650-23 treatment (Supplementary Figure 7B) . Transcriptional alterations of a subset of cell-cycle regulators were confirmed by qPCR in two AML cell lines (Supplementary Figure 7C ). In addition, our group has previously reported that Replication Factor C3 (RFC3), a member of the PCNA DNA replication complex, is downregulated following CREB knockdown in AML cells, which is associated with G 1 /S transition arrest. 49 Levels of RFC3 also decreased following XX-650-23 treatment (Figure 6c ).
DISCUSSION
Successful treatment of AML remains a major clinical challenge, and progress in our ability to treat AML patients will depend on the development of effective approaches associated with minimal toxicity. Here, we provide the first evidence that a novel small molecule that inhibits the transcription factor CREB may offer a unique, effective and non-toxic approach to treat AML patients. CREB is an ideal target for AML therapy, given that CREB overexpression is associated with a worse prognosis and knockdown of CREB does not affect normal HSC activity. Previous work facilitated the synthesis of a novel inhibitor of CREB function, XX-650-23, which our data establish as a competitive inhibitor of CBP-CREB interaction. We offer this study as 'proof-of-principle' that CREB inhibition is a viable approach to AML therapy.
Developing 'targeted therapy' for AML connotes both that the agent is targeted to a specific function or molecule within AML cells, and that the agent's toxicity is specific to AML cells. On the basis of our data, we postulate that the specificity with which XX-650-23 disrupts the CREB-CBP interaction defines its selective toxicity to AML cells. Biochemical evidence supports that XX-650-23 binds CBP and physically disrupts the CREB-CBP interaction. Our whole-transcriptome and genome acetylation studies provide evidence that the CREB-CBP interaction is specifically disrupted. The almost exclusive reduction in H3K27 acetylation at CREBbound genomic loci reflects the absence of CBP docking at, and only at, these sites. Furthermore, the activity of other transcription factors that also bind the CBP KIX domain was not affected. These data provide evidence that XX-650-23 exerts 'on-target' effects. Within the set of genes bound by CREB, the transcription of hundreds of genes was significantly (450%) downregulated. It is not surprising that we did not observe a significant reduction in transcription of all CREB-bound genes, as expression of most eukaryotic genes is determined by input from unique sets of diverse transcription factors. Our data demonstrate that key CREB-bound factors that regulate the cell cycle and apoptosis are downregulated, and sufficient to cause AML cell-cycle arrest and apoptosis in vitro and in vivo.
Targeting the activity of specific transcription factors for the treatment of leukemia has begun to show promise in a number of pre-clinical studies. The interaction of CBP with βand γ-catenin has recently been targeted using a small molecule, and this strategy was effective against both primary and relapsed ALL. 31 Another group recently demonstrated the efficacy of targeting the mutant fusion transcription factor CBPβ-SMMHC, which drives inv (16) + AML, 32 and the critical interaction between menin and MLL fusion proteins, which drives subtypes of both AML and ALL, has also been successfully targeted. 50 The data presented here similarly provide 'proof-of-principle' that CREB can be targeted for the treatment of AML, and lay the groundwork for advancing this strategy to the clinical arena.
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